June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Variation in the use of bevacizumab and ranibizumab for diabetic macular edema
Author Affiliations & Notes
  • Annie Wu
    Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
  • Connie Wu
    Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
  • Paul B Greenberg
    Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
    Section of Ophthalmology, VA Medical Center, Providence, Rhode Island, United States
  • Fei Yu
    Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Flora Lum
    American Academy of Ophthalmology, San Francisco, California, United States
  • Anne Coleman
    Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Annie Wu, None; Connie Wu, None; Paul Greenberg, None; Fei Yu, None; Flora Lum, None; Anne Coleman, Aerie (C), Alcon (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2909. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Annie Wu, Connie Wu, Paul B Greenberg, Fei Yu, Flora Lum, Anne Coleman; Variation in the use of bevacizumab and ranibizumab for diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2909.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the distribution of intravitreal bevacizumab and ranibizumab injections for diabetic macular edema (DME) in the United States (US) with the goal of improving cost-effective medication utilization.

Methods : A 5% sample of Medicare beneficiaries in the Carrier file (Part B Medicare claims file) was obtained to identify all beneficiaries with an ICD-9-CM code for DME (362.07) from 2010 to 2013. Patient characteristics including age, gender, and Charlson Comorbidity Index (CCI) were collected. HSCPS codes for bevacizumab (J3590, J9035, and J3490) and for ranibizumab (J2778) were used to identify the mode of treatment and associated billing and reimbursement amounts for each patient. Geographic variation was determined by comparing injection frequencies across the nine US census divisions using Chi-squared analysis.

Results : The 2010-2013 sample included 5,290 Medicare beneficiaries with DME: 34.6% were aged 65-69, 53.7% were female, 78.8% were white, and 36.0% had a CCI score of ≥5. Overall, there was a greater frequency of bevacizumab use (86.4%) compared to ranibizumab use (13.6%) for the sample of 5,290 patients with DME. The highest frequencies of bevacizumab use were in the Mountain (92.2%), West South Central (91.7%) and East South Central (90.4%) divisions. The highest frequencies of ranibizumab use were in the Mid Atlantic (24.0%), West North Central (19.9%) and New England (16.6%) divisions. The frequencies of bevacizumab and ranibizumab injections for DME varied significantly between the US census divisions (p<0.0001).

Conclusions : Bevacizumab is used more frequently than ranibizumab for the treatment of DME among Medicare beneficiaries, with significant geographic variation in injection frequencies of the two anti-VEGF agents. Further characterization of the factors contributing to this variation may help direct cost-effective strategies for the management of DME.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×